» Articles » PMID: 38016356

Nanostructures for Site-specific Delivery of Oxaliplatin Cancer Therapy: Versatile Nanoplatforms in Synergistic Cancer Therapy

Abstract

As a clinically approved treatment strategy, chemotherapy-mediated tumor suppression has been compromised, and in spite of introducing various kinds of anticancer drugs, cancer eradication with chemotherapy is still impossible. Chemotherapy drugs have been beneficial in improving the prognosis of cancer patients, but after resistance emerged, their potential disappeared. Oxaliplatin (OXA) efficacy in tumor suppression has been compromised by resistance. Due to the dysregulation of pathways and mechanisms in OXA resistance, it is suggested to develop novel strategies for overcoming drug resistance. The targeted delivery of OXA by nanostructures is described here. The targeted delivery of OXA in cancer can be mediated by polymeric, metal, lipid and carbon nanostructures. The advantageous of these nanocarriers is that they enhance the accumulation of OXA in tumor and promote its cytotoxicity. Moreover, (nano)platforms mediate the co-delivery of OXA with drugs and genes in synergistic cancer therapy, overcoming OXA resistance and improving insights in cancer patient treatment in the future. Moreover, smart nanostructures, including pH-, redox-, light-, and thermo-sensitive nanostructures, have been designed for OXA delivery and cancer therapy. The application of nanoparticle-mediated phototherapy can increase OXA's potential in cancer suppression. All of these subjects and their clinical implications are discussed in the current review.

Citing Articles

Molecular Hydrogen Protects against Various Tissue Injuries from Side Effects of Anticancer Drugs by Reducing Oxidative Stress and Inflammation.

Hirano S, Takefuji Y Biomedicines. 2024; 12(7).

PMID: 39062164 PMC: 11274581. DOI: 10.3390/biomedicines12071591.


T Cell and Natural Killer Cell Membrane-Camouflaged Nanoparticles for Cancer and Viral Therapies.

Ozsoy F, Mohammed M, Jan N, Lulek E, Ertas Y ACS Appl Bio Mater. 2024; 7(5):2637-2659.

PMID: 38687958 PMC: 11110059. DOI: 10.1021/acsabm.4c00074.

References
1.
El-Hammadi M, Delgado A, Melguizo C, Prados J, Arias J . Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int J Pharm. 2016; 516(1-2):61-70. DOI: 10.1016/j.ijpharm.2016.11.012. View

2.
Boedtkjer E, Pedersen S . The Acidic Tumor Microenvironment as a Driver of Cancer. Annu Rev Physiol. 2019; 82:103-126. DOI: 10.1146/annurev-physiol-021119-034627. View

3.
Naguib Y, Cui Z . Nanomedicine: the promise and challenges in cancer chemotherapy. Adv Exp Med Biol. 2014; 811:207-33. DOI: 10.1007/978-94-017-8739-0_11. View

4.
Adhikari H, Nath Yadav P . Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action. Int J Biomater. 2019; 2018:2952085. PMC: 6332982. DOI: 10.1155/2018/2952085. View

5.
Baghdan E, Pinnapireddy S, Strehlow B, Engelhardt K, Schafer J, Bakowsky U . Lipid coated chitosan-DNA nanoparticles for enhanced gene delivery. Int J Pharm. 2017; 535(1-2):473-479. DOI: 10.1016/j.ijpharm.2017.11.045. View